<DOC>
	<DOCNO>NCT02676856</DOCNO>
	<brief_summary>The purpose study evaluate efficacy hematopoietic stem cell microtransplantation acute myeloid leukemia ( AML ) patient receive hematopoietic stem cell transplantation ( HSCT ) .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Microtransplantation AML</brief_title>
	<detailed_description>Despite allogeneic HSCT curative therapy AML , patient receive transplantation due intolerance transplant-related toxicity unwillingness HSCT . For patient , microtransplantation seem optional therapy . However , efficacy still remain unclear .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>AML patient receive induction chemotherapy moderatehigh dose AraC 3 course consolidate chemotherapy Intolerance unwillingness allogeneic HSCT Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>hematopoietic stem cell microtransplantation</keyword>
</DOC>